MAPT and Parkinson disease: To demonstrate the potential of exon inclusion as a treatment for frontotemporal dementia with parkinsonism linked to chromosome 17, AOs were directed against the splice junctions of exon 10 of MAPT pre-mRNA to efficiently induce its exclusion in an in vitro system [21].